FiercePharma1d
Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...
Deccan Herald20m
FDA approves the first new schizophrenia drug in decades
The Food and Drug Administration on Thursday approved the first novel antipsychotic treatment in decades, a drug developed to ...
Pharmaceutical Technology13h
BMS wins approval for schizophrenia drug acquired from Karuna
The FDA has approved the first treatment for schizophrenia that targets cholinergic receptors rather than dopamine receptors.
BioWorld7h
US FDA clears Cobenfy, first new schizophrenia drug in decades
The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating ...
C&EN1d
FDA approves Cobenfy, a first-in-class schizophrenia drug
The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers Squibb (BMS) last year for $14 billion. This is the first new class of treatment for the psychiatric disorder since ...
KALW1h
A new kind of drug for schizophrenia promises fewer side effects
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Des Moines Register9h
This FDA-approved drug promises a new way to treat schizophrenia
The promising drug combination was discovered and tested by Karuna Therapeutics, which Bristol Myers Squibb acquired in March. Bristol Myers Squibb will sell the drug combination under the brand name ...
Zacks.com on MSN15h
Bristol Myers Stock Up on FDA Nod for Schizophrenia Treatment
Bristol Myers Squibb BMY announced that the FDA has approved xanomeline and trospium chloride (formerly KarXT), an oral ...
Bristol Myers wins US FDA approval for new type of schizophrenia drug
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
THE WEEK4d
The 'game-changing' treatment for schizophrenia
Developed by Karuna Therapeutics, now part of Bristol Myers Squibb (BMS), it works by targeting receptors in the brain that modulate dopamine release, rather than blocking it directly. Results of ...
Business Wire8d
GC Therapeutics Launches to Scale and Unlock the Next Generation of Cell Therapy
Karuna Therapeutics, former EVP, Eli Lilly and Company, co-founder and board chair, Rapport Therapeutics and Seaport Therapeutics “GCTx’s TFome platform represents one of the most innovative ...